Quest Diagnostics Reports Q3 2026 Financial Results and Raises Full-Year Guidance

Quest Diagnostics Incorporated reported Q3 2026 adjusted earnings per share of $3.00, exceeding the FactSet consensus estimate of $2.87, and quarterly revenue of $3.10 billion, surpassing expectations of $3.05 billion. Following these results, the company raised its full-year 2026 revenue guidance to between $12.07 billion and $12.11 billion, up from $12.02 billion. Additionally, the adjusted earnings per share guidance for the full year was updated to a range of $11.25 to $11.35, exceeding the previous estimate of $11.20.